<DOC>
	<DOC>NCT00219323</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES</brief_summary>
	<brief_title>Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Allergic asthma patients Inadequately controlled patients History of severe anaphylactoid or anaphylactic reactions Previous treatment with omalizumab History of cancer or cancer Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma, IgE, Omalizumab</keyword>
</DOC>